-
公开(公告)号：US10507201B2
公开(公告)日：2019-12-17
申请号：US16289612
申请日：2019-02-28
Applicant: NOVARTIS AG
Inventor： Nicole Buschmann , Robin Alec Fairhurst , Pascal Furet , Diana Graus Porta , Carolina Haefliger , Bo Han , Thomas Knöpfel , Catherine Leblanc , Lv Liao , Robert Mah , Masato Murakami , Pierre Nimsgern , Michael Palmer , Dale Porter , Sebastien Ripoche , Can Wang , Youzhen Wang , Andreas Weiss , Jing Xiong , Xianglin Zhao
IPC: A61K31/475 , A61K31/4545 , A61K31/496 , A61K31/55 , A61P35/00 , A61K31/4375
Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
-
2.发明申请公开(公告)号：US20210121460A1
公开(公告)日：2021-04-29
申请号：US17042591
申请日：2019-03-29
Applicant: NOVARTIS AG
Inventor： Matthew John Meyer , Youzhen Wang
IPC: A61K31/506 , A61P35/00 , A61K31/5025 , A61K9/00
Abstract: The present invention relates to a pharmaceutical combination comprising dabrafenib, trametinib and an Erk-inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.
-
![Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof](/abs-image/US/2014/12/09/US08906936B2/abs.jpg.150x150.jpg)
3.发明授权Pharmaceutical combination comprising co-administration of taxane and N-(1-cyclohexyl-2-{2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or pharmaceutically acceptable salt(s) thereof 有权药物组合包括联合给予紫杉烷和N-（1-环己基-2- {2- [4-（4-氟 - 苯甲酰基） - 噻唑-2-基] - 吡咯烷-1-基} -2-氧代 - 乙基）-2-甲基氨基 - 丙酰胺或其药学上可接受的盐公开(公告)号：US08906936B2
公开(公告)日：2014-12-09
申请号：US13761634
申请日：2013-02-07
Applicant: Novartis AG
Inventor： Michael Rugaard Jensen , Christopher Sean Straub , Leigh Zawel , Mary Ann Tran , Youzhen Wang
IPC: A01N43/42 , A61K31/44 , A61K31/16 , A61K31/425 , A61K45/06 , A61K31/437 , A61K31/475 , C07D471/04 , A61K31/337
CPC classification number: A61K31/437 , A61K31/16 , A61K31/337 , A61K31/425 , A61K31/475 , A61K45/06 , C07D471/04 , A61K2300/00
Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
Abstract translation: 本发明提供药物组合，其包含：a）抑制Smac蛋白与IAP结合的化合物; 和b）紫杉烷类，以及使用这种组合治疗或预防增殖性疾病的方法。
-
公开(公告)号：US20130217719A1
公开(公告)日：2013-08-22
申请号：US13761634
申请日：2013-02-07
Applicant: Novartis AG
Inventor： Michael Rugaard Jensen , Christopher Sean Straub , Leigh Zawel , Mary Ann Tran , Youzhen Wang
IPC: A61K31/437 , A61K31/337 , C07D471/04
CPC classification number: A61K31/437 , A61K31/16 , A61K31/337 , A61K31/425 , A61K31/475 , A61K45/06 , C07D471/04 , A61K2300/00
Abstract: The invention provides a pharmaceutical combination comprising: a) compounds that inhibit the binding of the Smac protein to IAPs; and b) a taxane, and a method for treating or preventing a proliferative disease using such a combination.
Abstract translation: 本发明提供药物组合，其包含：a）抑制Smac蛋白与IAP结合的化合物; 和b）紫杉烷类，以及使用这种组合治疗或预防增殖性疾病的方法。
-
-
-
Search Results
4
records
(took 0.012 seconds)
